Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine if LCI699, thorough reductions in aldosterone, can lower BP in patients with Primary hyperaldosteronism.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Novartis
NCT05797558 · Primary Hyperaldosteronism Due to Adrenal Adenoma
NCT03474237 · Adrenal Adenoma, Cushing Syndrome, and more
NCT04251780 · Primary Hyperaldosteronism, Electrolyte Disturbance
NCT03405025 · Primary Hyperaldosteronism, Primary Hyperaldosteronism Due to Adrenal Adenoma
NCT01567111 · Primary Hyperaldosteronism
Novartis Investigator Site
France
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions